

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company Roche (alectinib)	General All Wales Therapeutics and Toxicology
 Roche (alectinib) Patient/carer groups ALK Positive UK Asthma and Lung UK Black Health Agency for Equality Cancer Black Care Cancer Equality Cancer52 Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Oncogene-Driven Lung Cancer Patient Alliance Roy Castle Lung Cancer Foundation Ruth Strauss Foundation 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services
South Asian Health Foundation	Committee
Specialised Healthcare AllianceTenovus Cancer CareUK Lung Cancer Coalition	Comparator companiesAspire Pharma (pemetrexed)Bristol Myers Squibb (paclitaxel)
 Healthcare professional groups Association of Cancer Physicians Association of Respiratory Nurse Specialists British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Thoracic Oncology Group British Thoracic Society Cancer Research UK 	 Dr Reddy's Laboratories (pemetrexed) Eli Lilly (pemetrexed) Genus Pharmaceuticals (pemetrexed) Medac (oxaliplatin) Merck Sharp & Dohme UK (pembrolizumab) Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed) Ranbaxy UK [a Sun Pharmaceuticals company] (oxaliplatin) Sandoz (cisplatin, pemetrexed)

Final stakeholder list for the appraisal of alectinib for adjuvant treatment of ALK-positive non-smallcell lung cancer [ID6368] Issue date: March 2024



Consultees	Commentators (no right to submit or appeal)
 Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel) Teva UK (paclitaxel) Zentiva (pemetrexed) Relevant research groups British Association of Lung Research Cochrane Airways Group Cochrane Lung Cancer Group Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health & Care Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Final stakeholder list for the appraisal of alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]

Issue date: March 2024



Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.